01Role and principlesWho benefits and the main preventive aims.
Surveillance is active observation of an asymptomatic aneurysm below the usual elective repair threshold. Its purpose is to detect expansion soon enough for specialist reassessment while avoiding the immediate operative risk of repairing every small aneurysm. In the NHS AAA Screening Programme in England, a small AAA of 3.0–4.4 cm receives 12-monthly ultrasound and a medium AAA of 4.5–5.4 cm receives 3-monthly ultrasound. NICE adopts the same frequency for asymptomatic AAA surveillance in UK clinical care.
The numbers are meaningful only with a consistent technique. NICE and the England programme specify maximum anterior-posterior diameter on ultrasound measured inner wall to inner wall. Screening technicians record longitudinal and transverse AP measurements. CT angiography is used to define operative anatomy, but CT and ultrasound may differ because of plane and calliper placement; an apparent jump should therefore prompt image and method review rather than automatic labelling as biological growth.
Surveillance must also manage the person, not only the sac. AAA is a marker of high cardiovascular risk. NICE recommends smoking-cessation referral for smokers, hypertension care under national guidance, and secondary cardiovascular prevention information and interventions. Symptoms override the calendar: new persistent abdominal or back pain, tenderness, syncope or haemodynamic compromise requires immediate assessment for symptomatic or ruptured AAA even when the most recent measurement was below 5.5 cm.
Key points
- England screens small AAA 3.0–4.4 cm with ultrasound every 12 months.
- England screens medium AAA 4.5–5.4 cm with ultrasound every three months.
- At least 5.5 cm or growth over 1 cm yearly triggers vascular referral without delay.
- New abdominal or back pain requires urgent symptomatic assessment regardless of last diameter.
- Compare serial scans only after checking modality, plane and calliper convention.
- Smoking cessation and blood-pressure treatment address modifiable rupture and cardiovascular risk.
- Surveillance detects change; it is not drug treatment for aneurysm shrinkage.
- An incidental diagnostic AAA stays with vascular services rather than entering programme surveillance.
02Assessment and patient selectionRisk features, eligibility and important cautions.
A maximum AP inner-to-inner ultrasound diameter from 3.0 through 4.4 cm enters annual surveillance.
A maximum AP inner-to-inner diameter from 4.5 through 5.4 cm enters three-month surveillance.
Growth exceeding 1 cm in one year meets the programme referral trigger and NICE repair-consideration criterion.
New abdominal or back pain in a patient with known AAA requires urgent vascular assessment rather than waiting for the next scan.
Repeated non-attendance or relocation can create an unrecognised surveillance gap and requires active tracking.
03Baseline assessmentMeasurements that guide the plan and track progress.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Serial aortic ultrasoundFirst step - Why
- Track aneurysm diameter using a reproducible low-risk method
- Interpretation and limitations
- Use maximum AP inner-to-inner measurements; allocate 12-monthly or 3-monthly review from the programme diameter band.
- 02
Prior-image comparison - Why
- Verify true growth before changing the management pathway
- Interpretation and limitations
- Check dates, plane, modality and callipers; discordant CT and ultrasound values do not automatically prove rapid expansion.
- 03
Thin-slice arterial CT angiography - Why
- Map anatomy after a repair threshold is reached
- Interpretation and limitations
- CTA defines proximal neck, branch vessels and iliac access for planning, but does not replace the ultrasound convention used in NICE size thresholds.
- 04
Cardiovascular risk assessment - Why
- Identify modifiable risks associated with AAA and competing events
- Interpretation and limitations
- Smoking, blood pressure, lipids, diabetes and established vascular disease guide prevention under their relevant national guidelines.
- 05
Immediate bedside ultrasound - Why
- Assess a known AAA patient with new concerning symptoms
- Interpretation and limitations
- A positive, unavailable or non-diagnostic study with persistent suspicion requires immediate regional vascular discussion.
04InterventionsLifestyle, treatment and escalation options.
01Surveillance routeStable asymptomatic aneurysmFirst stepA reproducible programme ultrasound remains below the referral threshold+
- 1Confirm the maximum AP inner-to-inner diameter and prior imaging method.
- 2Schedule 12-month ultrasound for 3.0–4.4 cm or three-month ultrasound for 4.5–5.4 cm.
- 3Review smoking, blood pressure and wider secondary cardiovascular prevention needs.
- 4Explain urgent symptoms and document who owns recall and result review.
02Escalation routeGrowth or size triggerEscalationUltrasound reaches 5.5 cm or growth exceeds 1 cm yearly+
- 1Check image quality and confirm the serial measurement convention used.
- 2Contact the programme office and arrange vascular referral without delay.
- 3Ensure the vascular unit receives the report and assumes ongoing responsibility.
- 4Use CTA within the specialist pathway when elective repair is evaluated.
03Symptom routePain during surveillanceA known AAA patient develops new abdominal or back pain+
- 1Treat the presentation as potentially symptomatic or ruptured AAA immediately.
- 2Request bedside ultrasound while beginning clinical resuscitation and monitoring.
- 3Discuss immediately with the regional vascular service when suspicion persists.
05Targets, monitoring and follow-upResponse, safety and longer-term review.
- Track every scan invitation, attendance, measurement, result letter and next due date.
- Keep quarterly surveillance after a single subsequent value below 4.5 cm in programme practice.
- Confirm vascular referral and handover when 5.5 cm or rapid-growth criteria are met.
- Review smoking status and blood-pressure care at surveillance contacts.
- Reassess surveillance benefit when repair would no longer be acceptable or feasible.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
England interval bands
The England programme intentionally uses annual surveillance for 3.0–4.4 cm and quarterly surveillance for 4.5–5.4 cm; these intervals differ from ESVS research-based schedules.
ESVS European schedule
ESVS 2024 suggests sex-specific ultrasound intervals: in men, three-yearly at 30–39 mm, annual at 40–49 mm and six-monthly from 50 mm; in women, six-monthly begins at 45 mm.
Futility discussion
ESVS advises considering discontinuation when the aneurysm is unlikely to reach a repair threshold within life expectancy, repair is unsuitable, or informed preference is conservative management.
No size-only shortcut
NICE considers repair for symptomatic AAA, asymptomatic AAA at least 5.5 cm, or an asymptomatic aneurysm over 4.0 cm growing more than 1 cm in one year.
Cardiovascular burden
A patient may be more likely to experience myocardial infarction or stroke than rupture while the aneurysm is small, so prevention is a core surveillance task.
07Common pitfallsFrequent interpretation and management errors.
- 01
Waiting for 5.5 cm despite new pain confuses elective thresholds with emergency symptoms.
- 02
Calling mixed CT and ultrasound values rapid growth can trigger an erroneous decision.
- 03
Using ESVS intervals as the England screening programme schedule misstates national practice.
- 04
Assuming surveillance itself reduces cardiovascular risk neglects smoking and blood-pressure management.
- 05
Allowing programme and vascular services to duplicate follow-up creates unclear clinical ownership.